Clinical Trial Update: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 [Phase 3]

View source ↗

Summary

Phase 3 extension study updates safety of monthly recombinant Factor XIII replacement in congenital Factor XIII deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Xiii Deficiency

Drugs mentioned

• recombinant Factor XIII replacement therapy (Factor XIII)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2016-12-13